Difference between revisions of "Doxorubicin (Adriamycin)"
Jump to navigation
Jump to search
m |
m |
||
| Line 95: | Line 95: | ||
|Cloridrato DE | |Cloridrato DE | ||
|Doxorrubicina Colhidrol | |Doxorrubicina Colhidrol | ||
| − | |||
|Deldoxin | |Deldoxin | ||
|Dicladox | |Dicladox | ||
|Dobicin | |Dobicin | ||
| + | |Dobixin | ||
|- | |- | ||
| − | |||
|Doxo | |Doxo | ||
|Doxobin | |Doxobin | ||
| Line 108: | Line 107: | ||
|Doxolem | |Doxolem | ||
|Doxonolver | |Doxonolver | ||
| + | |Doxor | ||
|- | |- | ||
| − | |||
|Doxorrubicina | |Doxorrubicina | ||
|Doxoruben | |Doxoruben | ||
| Line 117: | Line 116: | ||
|Doxorubin | |Doxorubin | ||
|Doxotec | |Doxotec | ||
| + | |Doxtie | ||
|- | |- | ||
| − | |||
|Duxocin | |Duxocin | ||
|Evacet | |Evacet | ||
| Line 126: | Line 125: | ||
|Ifadox | |Ifadox | ||
|Kemodoxa | |Kemodoxa | ||
| + | |Lipodox | ||
|- | |- | ||
| − | |||
|Lyphidox | |Lyphidox | ||
|Nagun | |Nagun | ||
| Line 135: | Line 134: | ||
|Onkodox | |Onkodox | ||
|Onkostatil | |Onkostatil | ||
| + | |Pallagicin | ||
|- | |- | ||
| − | |||
|Ranxas | |Ranxas | ||
|Rastocin | |Rastocin | ||
Revision as of 16:35, 17 May 2022
General information
Class/mechanism: Anthracycline; binds and intercalates into DNA, inhibiting nucleotide replication and DNA/RNA polymerase activity. Intercalation of DNA triggers DNA cleavage via topoisomerase II. Toxic effects on organs may be related to cell membrane lipid binding activities; enzymatic electron reduction of doxorubicin creates reactive species, e.g. hydroxyl free radicals OH-, which has been implicated in cardiotoxicity by means of Cu (II) and Fe (III) reduction.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adrenocortical carcinoma
- Adult T-cell leukemia-lymphoma
- Anaplastic large cell lymphoma
- B-cell acute lymphoblastic leukemia
- Bladder cancer
- Breast cancer
- Burkitt lymphoma
- Cutaneous basal cell carcinoma
- Cutaneous squamous cell carcinoma
- Diffuse large B-cell lymphoma
- Endometrial cancer
- Ewing sarcoma
- Follicular lymphoma
- Hepatoblastoma
- Hepatocellular carcinoma
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Kaposi sarcoma
- Malignant pleural mesothelioma
- Mantle cell lymphoma
- Marginal zone lymphoma
- Mediastinal gray-zone lymphoma
- Multiple myeloma
- Neuroblastoma
- Osteosarcoma
- Pancreatic NET
- Peripheral T-cell lymphoma
- Post-transplant lymphoproliferative disorder
- Primary mediastinal B-cell lymphoma
- Rhabdomyosarcoma
- Sarcomatoid renal cell carcinoma
- Soft tissue sarcoma
- Thymoma
- Transformed lymphoma
- Transplant conditioning regimens
- Waldenström macroglobulinemia
Diseases for which it was used
- Acute myeloid leukemia
- Chronic lymphocytic leukemia
- Gastric cancer
- Non-small cell lung cancer
- Ovarian cancer
- Prostate cancer
- Small cell lung cancer
- Testicular cancer
Patient drug information
- Doxorubicin (Adriamycin) patient drug information (Chemocare)[3]
- Doxorubicin (Adriamycin) package insert page 1[1]
- Doxorubicin (Adriamycin) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 8/7/1974: Initial FDA approval
- 5/8/2003: Earliest date with label information at Drugs @ FDA: "Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.
Also known as
- Code name: FI-106
- Generic names: ADM, doxorubicin hydrochloride, hydroxydaunorubicin
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Adriablastina | Adriacept | Adriacin | Adriamycin | Adriamycine | Adriblastin | Adriblastina | Adriblastine |
| Adricept | Adricin | Adrim | Adrimedac | Adrosal | Antraciclin | Biorrub | Biorubina |
| Cadria | Carcinocin | Cloridrato DE | Doxorrubicina Colhidrol | Deldoxin | Dicladox | Dobicin | Dobixin |
| Doxo | Doxobin | Doxo Cell | Doxocris | Doxokebir | Doxolem | Doxonolver | Doxor |
| Doxorrubicina | Doxoruben | Doxorubicina | Doxorubicine | Doxorubicinum | Doxorubin | Doxotec | Doxtie |
| Duxocin | Evacet | Farmiblastina | Fauldoxo | Flavicina | Ifadox | Kemodoxa | Lipodox |
| Lyphidox | Nagun | Neoxane | Nuaze | Oncodria | Onkodox | Onkostatil | Pallagicin |
| Ranxas | Rastocin | Ribodoxo | Roxorin | Rubex | Varidoxo | Zodox | |
References
Categories:
- Drugs
- Intra-arterial medications
- Intravenous medications
- Intravesical medications
- Vesicant
- Anthracyclines
- Topoisomerase inhibitors
- Adrenocortical carcinoma medications
- Adult T-cell leukemia-lymphoma medications
- Anaplastic large cell lymphoma medications
- B-cell acute lymphoblastic leukemia medications
- Bladder cancer medications
- Breast cancer medications
- Burkitt lymphoma medications
- Cutaneous basal cell carcinoma medications
- Cutaneous squamous cell carcinoma medications
- Diffuse large B-cell lymphoma medications
- Endometrial cancer medications
- Ewing sarcoma medications
- Follicular lymphoma medications
- Hepatoblastoma medications
- Hepatocellular carcinoma medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Kaposi sarcoma medications
- Malignant pleural mesothelioma medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Multiple myeloma medications
- Neuroblastoma medications
- Osteosarcoma medications
- Pancreatic NET medications
- Peripheral T-cell lymphoma medications
- Post-transplant lymphoproliferative disorder medications
- Primary mediastinal B-cell lymphoma medications
- Rhabdomyosarcoma medications
- Sarcomatoid renal cell carcinoma medications
- Soft tissue sarcoma medications
- Thymoma medications
- Transformed lymphoma medications
- Waldenström macroglobulinemia medications
- Acute myeloid leukemia medications (historic)
- Chronic lymphocytic leukemia medications (historic)
- Gastric cancer medications (historic)
- Non-small cell lung cancer medications (historic)
- Ovarian cancer medications (historic)
- Prostate cancer medications (historic)
- Small cell lung cancer medications (historic)
- Testicular cancer medications (historic)
- FDA approved in 1974
- WHO Essential Cancer Medicine